Focus: Biomed is a Sydney-based biotechnology company focused on small molecule development for neurological disorders. The company maintains a diverse pipeline spanning multiple therapeutic areas despite its stated neurology specialty.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
No open roles listed right now. Follow Biomed to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Generic proteasome inhibitor with mature market; minimal revenue upside but established market presence.
Help build intelligence for Biomed
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Biomed's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Radiopharmaceutical diagnostic with stable demand but low margin profile; no growth driver.
Diagnostic radiopharmaceutical with commodity pricing; niche market with limited upside.
3 discontinued, 10 duplicate formulations not shown
No open positions listed yet.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moSource: USCIS H-1B Employer Data Hub